A Study to Evaluate the Effect of Increased Stomach pH on Evacetrapib in Healthy Participants

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

34 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-01-31

Study Completion Date

2015-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate the effect of increased stomach pH on how much evacetrapib is found in the blood stream and how long the body takes to get rid of it when given to healthy participants. Information about any side effects that may occur will also be collected.

There are two parts to the study. Participation in both parts will be required.

The study will last approximately 30 days, not including screening.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Trial to Evaluate the Effect of Esomeprazole on the Pharmacokinetics of Emraclidine in Healthy Adult Participants

NCT06366243

Healthy Participants

COMPLETED PHASE1

A Study of Baricitinib and Omeprazole in Healthy Participants

NCT01925144

Healthy Volunteers

COMPLETED PHASE1

A Study to Explore the Effect of Acid-reducing Agents

NCT04935112

Healthy Adults

COMPLETED PHASE1

A Study to Examine the Effect of Omeprazole, Famotidine, and an Acidic Beverage on the Pharmacokinetics of Entinostat in Healthy Adult Subjects

NCT02922933

Volunteers Healthy Volunteers Human Volunteers +1 more

COMPLETED PHASE1

A Study to Evaluate the Effect of Food, Formulation, and a Proton Pump Inhibitor (PPI) on MK-1084 in Healthy Adult Participants (MK-1084-003)

NCT06619314

Healthy

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Evacetrapib

Single oral dose of evacetrapib administered alone on Day 1 of Period 1.

Group Type EXPERIMENTAL

Evacetrapib

Intervention Type DRUG

Administered orally

Omeprazole + Evacetrapib

In Period 2, participants will receive 40 mg oral dose of Omeprazole once daily (QD) on Days 8 through 20.

Evacetrapib will be co-administered once, orally on Day 14.

Group Type EXPERIMENTAL

Evacetrapib

Intervention Type DRUG

Administered orally

Omeprazole

Intervention Type DRUG

Administered orally

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Evacetrapib

Administered orally

Intervention Type DRUG

Omeprazole

Administered orally

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

LY2484595

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Overtly healthy participants, as determined by medical history and physical examination
* Females must be of non-child-bearing potential
* Have a body mass index of 18 to 32 kilograms per square meter (kg/m\^2)